Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61315
Type: Artigo de Periódico
Title: Prognostic significance of CD30 expression in diffuse large b-cell lymphoma: a systematic review with meta-analysis
Authors: Carla Isabelly Rodrigues- Fernandes
Pablo Agustin Vargas
Lucas Guimarães Abreu
Raghu Radhakrishnan
Danyel Elias da Cruz Perez
Gleyson Kleber Amaral- Silva
Rogério de Oliveira Gondak
Siavash Rahimi
Peter Brennan
Felipe Paiva Fonseca
Abstract: Background: CD30 is variably expressed in diffuse large B-cell lymphoma (DLBCL), but its prognostic potential for the affected patients remains debatable and unclear. Therefore, we aimed to determine the frequency of CD30 expression in DLBCL and its potential for prognostic determination. Methods: An electronic systematic review was performed using multiple databases, followed by a quantitative meta-analysis to assess the frequency of CD30 expression with positivity cut-off values of >0% and >20%, and to determine its association with clinicopathological features and patients' survival. Results: Using a cut-off value >0%, we observed that 3.5%-59.1% of the cases were considered positive for CD30. There was a significant association of the protein expression with a lower number of extra-nodal sites affected by the neoplasm, with Ann Arbor advanced stage, the absence of B-symptoms, the lack of MYC and BCL2 translocations, and a lower ECOG performance. Using a cut-off value >20%, we observed that 2.5%-36.7% of the cases were considered positive for CD30, being significantly associated with a lower number of extra-nodal sites affected by the neoplasm, Ann Arbor stages III/IV, non-GCB tumours, the lack of MYC and BCL2 translocations, and a lower ECOG value. CD30 expression was significantly associated with a better survival rate, regardless of what cut-off parameter was used. Conclusion: Despite variations in the cut-off values used to determine CD30 positivity in DLBCL, the expression of this protein seems to be associated with a higher survival rate and better prognosis.
Subject: Brentuximab vedotin
Ki-1 Antigen
Lymphoma, B-Cell
Lymphoma
Prognosis
Survival rate
Proteins
Systematic review
language: eng
metadata.dc.publisher.country: Brasil
Publisher: Universidade Federal de Minas Gerais
Publisher Initials: UFMG
metadata.dc.publisher.department: FAO - DEPARTAMENTO DE CLÍNICA
FAO - DEPARTAMENTO DE ODONTOPEDIATRIA E ORTODONTIA
Rights: Acesso Restrito
metadata.dc.identifier.doi: https://doi.org/10.1111/jop.13208
URI: http://hdl.handle.net/1843/61315
Issue Date: 2021
metadata.dc.url.externa: https://onlinelibrary.wiley.com/doi/10.1111/jop.13208
metadata.dc.relation.ispartof: Journal of Oral Pathology & Medicine
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.